Cardiac RehabilitationRECOVERNCT07096973
Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery
An observational study of Cardiac Rehabilitation and Heart Failure, run by Hochgebirgsklinik Davos at 1 site in Switzerland.
Trial summary
The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Rehabilitation, Heart Failure, Cardiac Arrest (CA)
- How many people
- 10,000 participants
- Where
- 1 siteSwitzerland
- Study dates
- 5 Aug 2025to 5 Aug 2040
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients referred to HGK for inpatient CR will be screened for eligibility according to inclusion and exclusion criteria. Study inclusion requires written informed consent, and the study and all -related procedures will be performed according to the Declaration of Helsinki. The study plans to enroll approximately 1'000 patients per year.
Who may be able to join
- Patients undergoing CR at the HGK
- Written informed consent
- Age ≥ 18 years
Who cannot join
- Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation
- Physical or psychological incapability to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Hochgebirgsklinik Davos
Davos, Kanton Graubünden, 7265
Researchteam Hochgebirgsklinik Davos, +41 81 417 40 60, research@hgk.ch
Reception/ Front Desk Hochgebirgsklinik Davos, +41 81 417 44 44, info@hgk.ch
About this study
The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension.
The principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos.
Read more
The study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries.
The primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up.
RECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.
- Conditions
- Cardiac Rehabilitation, Heart Failure, Cardiac Arrest (CA), ACS (Acute Coronary Syndrome), CABG, Valve Anomalies
- Keywords
- cardiovascular diseases, cardiac rehabilitation
- Medical subject headings
- Heart Failure, Heart Arrest, Acute Coronary Syndrome, Arrhythmias, Cardiac, Cardiovascular Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite of cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure
Outcome assessment will be conducted through a combination of structured telephone follow-up, systematic collection of relevant medical records from the time of inclusion to the follow-up visit, patient-completed questionnaires, and analysis of data from national health and mortality registries.
Measured: Follow-up 1, 5 and 10 years after inclusion
Incidence of all-cause rehospitalization post cardiac intervention or surgery
All-cause rehospitalization is defined as any unplanned hospital admission, regardless of cause, occurring following the index cardiac intervention or surgery. This includes admissions to any inpatient care facility for diagnostic, therapeutic, or emergency reasons, excluding planned elective procedures or routine follow-up admissions. Data will be obtained through structured follow-up, review of relevant hospital records, and linkage with national health insurance and hospital discharge registries to ensure comprehensive capture of rehospitalization events.
Measured: Follow-up 1, 5 and 10 years after inclusion
Secondary outcomes (5)
Patient reported quality of life (QoL)
Quality of life will be assessed using the EuroQol 5-Dimension (EQ-5D) questionnaire, a validated patient-reported outcome measure, administered at baseline and follow-up. The EQ-5D index score ranges from less than 0 (indicating health states worse than death) to 1 (perfect health), with higher scores reflecting better health-related quality of life. Changes in index scores will be analyzed to evaluate the effects of cardiac rehabilitation.
Measured: Follow-up 1, 5 and 10 years after inclusion
Re-surgery / Re-intervention
The incidence of repeat cardiovascular surgery or catheter-based interventions will be recorded within the follow-up period. This includes any planned or unplanned procedures related to the index condition (e.g., valve re-surgery, revascularization) and will be verified through medical records and registry linkage.
Measured: Follow-up 1, 5 and 10 years after inclusion
New-Onset Atrial Fibrillation
New-onset atrial fibrillation is defined as a first documented episode of AF after the index cardiac intervention or surgery, verified by ECG or rhythm monitoring. Occurrence will be assessed through medical records, telemetry data, and clinical follow-up.
Measured: Follow-up 1, 5 and 10 years after inclusion
Cognitive Function
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a standardized screening tool that evaluates multiple cognitive domains including memory, attention, executive function, and processing speed. Scores range from 0 to 30, with higher scores indicating better cognitive performance. Assessments will be conducted at baseline and follow-up to detect changes or cognitive decline following the intervention.
Measured: Follow-up 1, 5 and 10 years after inclusion
Functional Capacity
Functional capacity will be objectively assessed at baseline and discharge using the standardized 6-minute walk test (6MWT). At follow-up, functional status will be evaluated through patient-reported outcomes collected via structured interviews and questionnaires to estimate changes in physical performance and exercise tolerance over time.
Measured: Follow-up 1, 5 and 10 years after inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2025
- Study start5 Aug 2025
- Primary completion5 Aug 2035 (estimated)
- Study completion5 Aug 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac RehabilitationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Hochgebirgsklinik Davos
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07096973
- Sponsor's protocol ID
- 2024-02560
- Acronym
- RECOVER
- Status last verified
- Sep 2026
- First submitted
- 21 Jul 2025
- Last updated
- 29 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No